

Drug discovery
7
papers
On emerging therapies
Overview
Ring chromosome 18 syndrome is a rare genetic disorder caused by deletions at both ends of chromosome 18, resulting in a ring-shaped chromosome. Clinical features include developmental delay, intellectual disability (ranging from mild to severe), hypotonia, craniofacial abnormalities (microcephaly, hypertelorism, micrognathia), congenital heart defects (e.g., septal defects), skeletal anomalies, and growth retardation [1][3][14][18]. Diagnosis requires karyotyping and molecular confirmation (e.g., FISH or CMA) [1][18].
Burden
High morbidity: 71% of mortality occurs in infancy due to cardiac/respiratory complications [2][11]. Survivors often require lifelong care for intellectual/developmental disabilities [18].
Economic burden: Frequent specialized healthcare utilization (cardiology, neurology, orthopedics) and long-term supportive therapies [8][10].
Reduced quality of life: Limited independence in adulthood (minority achieve semi-independent living) [11][18].
Therapies
Multidisciplinary care: Early developmental interventions (physical/occupational/speech therapy), cardiac surveillance, and surgical correction for anomalies (cleft palate, cryptorchidism) [3][8][10].
Symptomatic management: Growth hormone therapy for deficiency, anticonvulsants for seizures (if present), and immunomodulation for recurrent infections [8][10][18].
Genetic counseling and prenatal testing for families with a history of chromosomal abnormalities [5][14].